PARD (Poniard Pharmaceuticals) Total Equity: $3.12 Mil (As of Sep. 2011)


What is Poniard Pharmaceuticals Total Equity?

Poniard Pharmaceuticals PARD Total Equity is $3.12 Mil as of Sep. 2011.

Poniard Pharmaceuticals's total equity for the quarter that ended in Sep. 2011 was $3.12 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Poniard Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Total Equity Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.89 89.11 47.65 23.64 8.45

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.13 8.45 9.34 6.28 3.12

Poniard Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Poniard Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2010 is calculated as

Total Equity=Total Assets(Q: Dec. 2010 )-Total Liabilities(Q: Dec. 2010 )
=11.643-3.19
=8.45

Poniard Pharmaceuticals's Total Equity for the quarter that ended in Sep. 2011 is calculated as

Total Equity=Total Assets(Q: Sep. 2011 )-Total Liabilities(Q: Sep. 2011 )
=7.736-4.619
=3.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $3.12 Mil mean?
Poniard Pharmaceuticals (PARD) has a Total Equity of $3.12 Mil as of Sep. 2011. The total amount of equity as record on a company's balance sheet. View historical data for Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Total Equity too high?
Poniard Pharmaceuticals' current Total Equity is $3.12 Mil.
How does Poniard Pharmaceuticals' Total Equity compare to OBMP and NSPX?
Poniard Pharmaceuticals' Total Equity of $3.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Total Equity is $3.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Total Equity of $3.12 Mil. The current Total Equity is $3.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Total Equity is $3.12 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.